Team of Scientists
Our core research team consists of Dr. Wei Liao’s research lab in UCLA Dental School and its five cooperative scientists. Over the past ten years, the Dr. Wei Liao’s research lab has focused on a liquid biopsy noninvasive DNA diagnosis and developed a series of core technologies. Now Dr. Liao Wei has returned and set up the team of product development, clinical validation and marketing, with the aim to carry out the commercialization of liquid biopsy noninvasive DNA precision diagnosis. The Scientists of our team will continuously develop and commercialize new technologies and products through EZlifeBio.
Dr. Wei Liao
CEO of EZlifeBio
Postdoctoral Scholar in Bioengineering at University of Pittsburg (2006). Researcher at UCLA School of Dentistry(2007). Vice President of AQS in Silicon Valley (2011-2014). Chief designer of EFIRM core technology and prototype.
Dr. David Wong
Expert in Biomarkers and Non-Invasive Diagnostics
Felix and Mildred Yip Professor at UCLA. Associate Dean of Research at UCLA. Director of UCLA Center for Oral/Head and Neck Oncology Research. World-class early detection and biomarker research scientist. Published over 230 scientific papers and co-authored 16 patents.
Dr. Fang Wei
Expert in Clinical Biosensor Development
PhD from Peking University Department ofChemistry (2003). Adj. Assistant Professor at UCLA.
Dr. Feng Li
Expert in DNA/RNA Biology
PhD in Biochemistry and Molecular biology from Shanghai Institute of Biochemistry and Cell Biology (2003). Assistant Researcher at UCLA.
Dr. David Chia
Expert in Early Cancer Detection Research
Professor of Pathology and Laboratory Medicine at UCLA. Member of the Early Detection Research Network (EDRN), a National Cancer Institute initiative.
Core Technologies
The world’s first apparatus which needs no tumor tissue sample but only 1ml of venous blood sample from patients. Samples do not require DNA extraction and amplification.
Features of Products
12

international patents

200

scientific papers

This technology was reported on July 1st, 2009 by “the Clinical Cancer Research” as the cover article, and praised as the top potential technology in 2009 as well.
Results of clinical trials of the first lung cancer DNA detection kit was published on November 15th, 2014 by “the Journal of Respiratory and Critical Care Medicine” as the cover article, and selected as the most influent research achievement in 2014 as well.
Collaboration
Clinical collaboration hospitals: EZlifeBio keeps close collaboration with Samsung Medical Hospital (South Korea), National Cheng Kung University Hospital (Taiwan) and several Chinese Hospitals with A3 level in order to carry out clinical trials and research.
(310)309-1777
10855 Le Conte Ave. Los Angeles, CA 90025
Copyright © 2015 Guangzhou EZlife Sci&Tech Co., Ltd. All rights reserved